Nomura Holdings
NBIX icon

Nomura Holdings’s Neurocrine Biosciences NBIX Stock Holding History

Nomura Holdings’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,500
Closed -$1.33M – 2324
2024
Q3 		$1.33M Sell
11,500
-5,300
-32% -$727K ﹤0.01% 1072
2024
Q2 		$2.31M Buy
+16,800
New +$2.3M ﹤0.01% 900
2022
Q4 		– Sell
-44,900
Closed -$4.77M – 1614
2022
Q3 		$4.77M Sell
44,900
-44,700
-50% -$4.54M 0.02% 571
2022
Q2 		$8.89M Buy
89,600
+25,800
+40% +$2.38M 0.03% 378
2022
Q1 		$6.1M Buy
+63,800
New +$5.41M 0.02% 554
2020
Q3 		– Sell
-80,000
Closed -$9.77M – 1398
2020
Q2 		$9.77M Buy
+80,000
New +$8.84M 0.03% 274
2020
Q1 		– Sell
-30,000
Closed -$3.22M – 1130
2019
Q4 		$3.22M Buy
+30,000
New +$3.14M 0.01% 535
2019
Q3 		– Sell
-20,000
Closed -$1.7M – 1335
2019
Q2 		$1.7M Buy
+20,000
New +$1.64M 0.01% 711

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Nomura Holdings's NBIX Position: Q2 2026 in Review

Nomura Holdings reduced its Neurocrine Biosciences (NBIX) stake by 42% in Q2 2026, selling an estimated $262K and leaving 2,432 shares worth $410K. The position accounts for ﹤0.01% of the portfolio, ranked #1559.

Nomura Holdings first reported a position in NBIX in Q2 2013 and has held it in 25 quarters since. The position peaked at $6.99M in Q3 2018. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Nomura Holdings held 2,432 shares of Neurocrine Biosciences worth $410K as of Q2 2026.
  • Nomura Holdings sold 1,768 Neurocrine Biosciences shares in Q2 2026, an estimated $262K.
  • Neurocrine Biosciences made up ﹤0.01% of Nomura Holdings's portfolio in Q2 2026, its #1559 holding.
  • Nomura Holdings first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 25 quarters since.
  • Nomura Holdings's Neurocrine Biosciences position peaked at $6.99M in Q3 2018.
  • 779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.